The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Outcomes in Patients with Rheumatic Diseases & COVID-19

Outcomes in Patients with Rheumatic Diseases & COVID-19

April 26, 2022 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Background & objectives: Patients with rheumatic and musculoskeletal diseases (RMDs) may be at an increased risk of SARS-CO-V2 infection as a result of underlying disease, associated comorbidities and use of potentially immunosuppressive treatments. Further, concern exists regarding whether individuals with rheumatic diseases potentially experience more severe COVID-19 and poorer outcomes. This study was undertaken to quantify the risk of SARS-CoV-2 infection in those with RMDs and describe clinical outcomes of COVID-19 in these patients.

You Might Also Like
  • COVID-19 Vaccination in Patients with Rheumatic Disease
  • COVID-19 Outcomes in Patients with Rheumatic Disease
  • Race Matters in COVID-19 Outcomes for Patients with Rheumatic Disease

Methods: Conway et al. conducted a systematic literature review using 14 databases from Jan. 1, 2019, to Feb. 13, 2021. They included observational studies and experimental trials in RMD patients that described comparative rates of SARS-CoV-2 infection, hospitalization, oxygen supplementation/intensive care unit (ICU) admission/mechanical ventilation or death attributed to COVID-19. Methodologic quality was evaluated using the Joanna Briggs Institute critical appraisal tools or the Newcastle-Ottawa scale. Risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated, as applicable for each outcome, using the Mantel-Haenszel formula with random effect models.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Results: Of the 5,799 abstracts screened, 100 studies met the criteria for inclusion in the systematic review, and 54 of 100 had a low risk of bias. Among the studies included in the meta-analyses, the researchers identified an increased prevalence of SARS-CoV-2 infection in patients with an RMD (RR 1.53 [95% CI 1.16–2.01]) compared with the general population. The odds of hospitalization, ICU admission and mechanical ventilation were similar in patients with and those without an RMD, whereas the mortality rate was increased in patients with RMDs (OR 1.74 [95% CI 1.08–2.80]). Fewer studies reported adjusted RRs for outcomes and, as a result, some were more likely to demonstrate no difference in risk.

Conclusion: Patients with RMDs have higher rates of SARS-CoV-2 infection and an increased mortality rate.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For full study details, including source material, refer to the full article.

Excerpted and adapted from:

Conway R, Grimshaw AA, Konig MF, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: A systematic literature review and meta-analysis. Arthritis Rheumatol. 2022 May;74(5).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Conditions Tagged With: Arthritis & Rheumatology, comorbidities, COVID-19, musculoskeletal disease, Rheumatic Disease

You Might Also Like:
  • COVID-19 Vaccination in Patients with Rheumatic Disease
  • COVID-19 Outcomes in Patients with Rheumatic Disease
  • Race Matters in COVID-19 Outcomes for Patients with Rheumatic Disease
  • Some Rheumatic Diseases Tied to Higher Risk of Severe COVID-19

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)